Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Crohns Colitis

Title: Journal of Crohn's & colitis

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1876-4479

ISSN (Print): 1873-9946

Publication date (Electronic): Dec 2015

Volume: 9

Issue: 12

Affiliations

[1 ] Université Paris Descartes, Sorbonne Paris Cité, Paris, France Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin-Pasteur, Paris, France INSERM, CIC 1417, Paris, France INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France odile.launay@cch.aphp.fr.

[2 ] AP-HP, Hôpital Cochin, Service de gastro-entérologie, Paris, France.

[3 ] AP-HP, Hôpital Cochin, Service de virologie, Paris, France.

[4 ] Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin-Pasteur, Paris, France.

[5 ] CHU Nantes, Hôtel Dieu, Nantes, France.

[6 ] Service d'Hépatogastroentérologie, Hôpital Nord, Amiens, France.

[7 ] Hôpital de l'Archet, Fédération d'Hépatogastroentérologie et de nutrition clinique, Nice, France.

[8 ] Service Hépatogastroentérologie et Nutrition, Hôpital Charles Nicolle, Rouen, France.

[9 ] INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France INSERM-CHRU de Lille, CIC 1403, Lille, France.

[10 ] Hôpital Beaujon, Service de Gastroentérologie et Assistance Nutritive, Clichy, France.

[11 ] Service de Gastroentérologie, Hôpital Bichat Claude Bernard, Paris, France.

[12 ] INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France INSERM, CIC de Montpellier, Hôpital Saint Eloi, Montpellier, France.

[13 ] Service d'Hépatogastroentérologie, Hôpital Haut-Lévêque, Pessac, France.

[14 ] Service de Gastroentérologie, CHU Jean Minjoz, Besançon, and Service d'Hépatogastroentérologie, Hôpital Claude Huriez, Lille, France.

[15 ] Service d'Hépato-gastroentérologie, Hôpital Saint-André, Bordeaux, France.

[16 ] Service de Gastroentérologie, AP-HP, Hôpital Saint-Louis, Paris, France.

[17 ] Service de Médecine Digestive et Hépatobiliaire, CHU Estaing, Clermont-Ferrand, France.

[18 ] Hôpitaux Universitaires de Strasbourg, Service d'Hépato gastroentérologie, Hôpital de Hautepierre, INSERM U1113, Strasbourg, France.

[19 ] INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France CHU Saint Etienne, Service des Maladies Infectieuses et tropicales, Saint Etienne, France.

[20 ] INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, Institut Pasteur, Paris, France.

[21 ] Université Paris Descartes, Sorbonne Paris Cité, Paris, France INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, INSERM, UMR_S 970, PARCC, Paris, France.

[22 ] Université Paris Descartes, Sorbonne Paris Cité, Paris, France AP-HP, Hôpital Cochin, Service de virologie, Paris, France.

[23 ] Service de médecine interne, AP-HP; Hôpital Ambroise Paré, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France.

[24 ] Service de Gastroentérologie, AP-HP, Hôpital Saint-Antoine et INSERM/UMRS 7203, UPMC Université de Paris VI, Paris, France.

[25 ] Département de santé publique, AP-HP, Hôpital Saint-Antoine, Paris, France Université Pierre et Marie Curie, UMR-S 1136, Paris, France INSERM, U1136, Paris, France.

Article

Publisher Item ID: jjv152

DOI: 10.1093/ecco-jcc/jjv152

PubMed ID: 26351392

SO-VID: 7fb0cfb3-e42a-479f-a2b6-caf8d5f4b8a6

History

Keywords: Vaccine immune response,safety,anti-TNF

Data availability:

Keywords: Vaccine immune response, safety, anti-TNF

Comments

Comment on this article

scite_

Cited by 22

See all cited by